This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field. In October, FDA announced seven new clinical trial grants awarded in fiscal year (FY) 2024 – including one for a Phase 3 trial – totaling $17.2
According to the United Nation’s 2024 World Population Prospects data, the global population of those 65 years old and over will grow from 0.8 From an aging population increasing health care demand to urgent, unmet medical needs, there are clear drivers to advance safe and effective medicines to patients faster than ever. billion in 2035.
Simpler ClinicalDevelopment From Day Dot blussier Fri, 06/21/2024 - 19:10 HTML Connecting the Dots With Comprehensive CRO Solutions When you CONNECT THE DOTS, you open a world of possibilities. Ready for a simpler drug development journey? At Altasciences, we connect the dots, so you don’t have to. WATCH THE VIDEO.
As we approach the end of 2023, it’s time to reflect on the past 12 months and how advances in drug development shaped the pharma and biotech industries. These shifts are a prelude to further change and progress in the clinical trial landscape in 2024. Five Predictions for the Drug Development Industry in 2024 1.
The PPD clinicalresearch business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.
Other drawbacks reported from working with these large CROs were: These performance disruptions and drawbacks have resulted in an environment of uncertainty among this CRO service provider segment in 2023, with likely ramifications extending into 2024 and beyond.
Insights in FIH studies provide valuable information on potential dosing, efficacy, and safety, and serve as a good guide for the regulatory requirements needed throughout clinicaldevelopment. jpg Tags Clinical Trials Weight 1
The growing demand for CRO services is fueled by the high costs of in-house drug discovery and development, the increasing number of products in the development pipeline, tech advancements, and the growing focus on precision and personalized medicine. from 2024 to reach US$129.8 billion by 2029. completed its acquisition of PPD.
Redig, SVP and Head of ClinicalDevelopment at HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The American Cancer Society for Oncology (ASCO) annual meeting is among the highlights of the clinical oncology calendar. By Amanda J. His remarks are worth reading in their entirety.
Currently there is no cure for hepatitis B, however there are several drugs in clinicaldevelopment to improve the lives and clinical outcomes for persons with chronic HBV infection, including functional cure strategies.
According to a report by Grand View Research, the global CRO services market was valued at approximately US$50.55 from 2024 to 2030. Ultimately, conducting an informed review of these cost factors will ensure companies make the best decision for their clinicaldevelopment and operational needs.
By Laura DiAngelo, MPH | Aug 2, 2024 6:30 PM CDT A refresher on FDA’s Diversity Action Plan (DAP) guidance: In April 2022, the FDA issued a draft guidance document on diversity in clinicalresearch programs. The agency issued a new draft guidance on DAPs in June 2024, several months after the Congressional deadline had passed.
Since these issues could occur during the investigational phase of clinicaldevelopment as well as in the post-marketing setting—and product status could very well differ by country/region—ICH members determined that these guidelines should be developed to facilitate the exchange of information in both settings.
BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”
PPD, Thermo Fisher Scientific’s clinicalresearch business, surveyed more than 150 biotech and biopharma leaders this year to assess trends in the drug development industry, yielding data we’ll cite throughout this blog. In addition, adaptive trial designs will contribute to innovations in clinicalresearch insights.
Differences in regulatory sentiments and industry sponsors’ subsequent clinicaldevelopment strategies historically restricted access based on geography. As we continue to explore current treatments and venture into new avenues of research, there lies hope for those affected by ALS.
FDA issued its draft guidance titled “ Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies ,” (the “Draft Guidance”) which replaces the previous pre-FDORA April 2022 draft guidance of the same name.
EMA finalizes clinical anticancer therapeutic guidance update In a newly finalized revision, the EMA’s guideline covering all aspects of clinicaldevelopment of anticancer therapeutics has expanded its already broad scope. The EMA started providing guidance on the clinicaldevelopment of anticancer therapeutics in 1996.
However, amid this progress, the complexities of drug development have never been more apparent. In 2024, the U.S. This decrease brings into sharp focus the growing challenges facing the field: Clinical trials now demand greater complexity, as well as increased data and diversity requirements.
In todays clinicalresearch landscape, it is both essential and challenging to accelerate clinical trials. However, achieving this requires drug developers to navigate a highly complex and competitive environment. Recognized as the 2024 No. 1 provider of clinicalresearch solutions , our teams deliver 1.5x
BY LAURA DIANGELO, MPH | JUN 26, 2024 8:17 PM CDT Quick background: FDA’s work to advance clinical trial diversity through prospective planning The FDA has longstanding policy interests focused on research study diversity. In April 2022, the FDA issued a draft guidance document on diversity in clinicalresearch programs.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
69 
Let's personalize your content